86% nocturia reduction in Direct-to-Bladder clinical trial.

This research by Dr Luna-Rivera is one of many pieces of evidence that Direct-to-Bladder therapies can produce better outcomes than taking the drug orally.

The most notable parts in this article are:

• Nocturia (passing urine in the night) decreased after 10 doses of bladder instillation.

• Urinary urgency reduced by 86%.

• Oral antimuscarinics are the first line of treatment but not always effective, …and have been associated with adverse effects that limit their use.

• This clinical trial show almost no presence of undesirable side effects, in addition to a notable improvement in quality-of-life.

We’ll be very interested in your feedback and questions

• See the Market Opportunity https://www.uropharma.com/market-opportunity

• See The Problem https://www.uropharma.com/the-problem

• See The Solution https://www.uropharma.com/the-solution

• See professionals’ testimonials https://www.uropharma.com/testimonials

• Investors: contact us at info@uropharma.com